Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis | PLOS ONE
![Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma - Li - Cancer Medicine - Wiley Online Library Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma - Li - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d02dec5f-87d6-4f52-a12a-32229c53b4f2/cam45422-toc-0001-m.jpg?trick=1669724604595)
Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma - Li - Cancer Medicine - Wiley Online Library
![PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma](https://i1.rgstatic.net/publication/326430488_Serum_free_light_chain_levels_and_renal_function_at_diagnosis_in_patients_with_multiple_myeloma/links/5b4d59a7a6fdcc8dae2468c2/largepreview.png)
PDF) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Frontiers | Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy Frontiers | Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy](https://www.frontiersin.org/files/Articles/901266/fonc-12-901266-HTML-r1/image_m/fonc-12-901266-g001.jpg)
Frontiers | Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy
![Getting the Most Out of Your Treatment: Your Role in Achieving Desired Outcomes in the Patient Journey - CONQUER: the patient voice Getting the Most Out of Your Treatment: Your Role in Achieving Desired Outcomes in the Patient Journey - CONQUER: the patient voice](https://conquer-magazine.com/images/special_issues/2021/November/table-1.png)
Getting the Most Out of Your Treatment: Your Role in Achieving Desired Outcomes in the Patient Journey - CONQUER: the patient voice
![Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-98803-1/MediaObjects/41598_2021_98803_Fig1_HTML.png)
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports
![Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees | Blood Cancer Journal Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-019-0186-8/MediaObjects/41408_2019_186_Fig1_HTML.png)